School of Medicine
Showing 141-150 of 167 Results
-
Edward Sheen
Adjunct Professor, Medicine - Med/Gastroenterology and Hepatology
BioDr. Edward Sheen is Chief Quality and Population Health Executive for L.A. Care. Serving more than 2.9 million members, L.A. Care is the largest publicly operated health plan in the country. As a public entity, its mission is to provide access to quality care for vulnerable and low-income communities and to support the safety net. Previously, he was Chief Population Health Officer, Senior Vice President for Health Catalyst and Chief Medical Officer, Market Development and Solution Design for Lumeris, a leading value-based care technology and services operator as well as 5.0 Star Medicare Advantage plan. He has worked with health systems and payers across the country to improve health outcomes, enhance patient experience, strengthen care provider engagement, reduce costs of care, and accelerate their journey towards accountable care. He is dedicated to achieving accessible, equitable, person-centered, and high performing care for all.
Dr. Sheen’s experience has bridged the public, private, non-profit, and academic sectors and additionally includes work with Stanford University, the White House, U.S. Department of Defense, U.S. Department of Health and Human Services, California State Assembly, Kaiser Family Foundation, Blue Shield, California and American Medical Associations, and Genzyme. In 2014, he was one of 15 Americans appointed by President Obama a nonpartisan White House Fellow. He subsequently served as a Special Assistant to the Secretary of Defense and Defense Department senior health policy advisor and was a recipient of the Office of the Secretary of Defense Medal for Exceptional Public Service. Dr. Sheen was a Term Member of the Council on Foreign Relations. He currently serves on the National Advisory Council on the National Health Service Corps, which advises the Secretary of Health and Human Services. He is Adjunct Professor of Medicine and Global Health Faculty Fellow at Stanford. He has a long-standing active commitment to mentoring, teaching, and medical education.
Dr. Sheen completed his Internal Medicine and Gastroenterology training at Stanford, received his MD from the University of California, San Francisco, and earned his MBA and MPH through scholarships from Stanford Graduate School of Business and Harvard School of Public Health, where he was also a Harvard Kennedy School Center for Public Leadership Zuckerman Fellow. He graduated magna cum laude from Brown University with a B.A. in Public Policy and induction into Phi Beta Kappa. -
Gulshan Singh
Postdoctoral Scholar, Gastroenterology
Current Research and Scholarly InterestsMy current research interest is to understand the host-microbial pathways in intestinal inflammation. I am working to explore cellular heterogeneity at single immune cell level in systemic and local regions of the intestine that are associated with different Inflammatory bowel disease conditions.
-
Sundeep Singh
Clinical Associate Professor, Medicine - Gastroenterology & Hepatology
BioAfter living and training throughout the country, I am excited to be part of the Stanford team. As a result of both my personal experiences and training, I am passionate about ensuring that patients receive appropriate diagnostic testing and treatment options in order to improve people's quality of life. In collaboration with my amazing colleagues, I am confident in the high quality and easily accessible care we are able to provide to patients across northern California.
While my interest is most in inflammatory bowel disease, I am also interested in the interaction between mental health, incentives, and emerging therapies in gastroenterology. -
Sidhartha Sinha
Assistant Professor of Medicine (Gastroenterology and Hepatology)
Current Research and Scholarly InterestsThere are two primary and overlapping emphases of my research, both of which are driven and united by needs-based innovation and translational potential:
(1) Understanding the microenvironment of the inflamed versus normal gut in order to identify better therapeutic targets for people with immune-¬mediated GI disorders. Here, our investigations include understanding the influence and interactions of pharmacologic and dietary interventions on gut microbiome/metabolomic changes and the host immune response. In the context of providing patients with new understanding and solutions for their disease, I have led and advised on the design of both pilot and large clinical trials (including new FDA approved therapies) for anti-inflammatory therapies;
(2) Applying novel approaches and technologies (including natural language processing, computer vision, and reinforcement learning) to identify and address unmet clinical needs. In this area we have ongoing and published efforts in my lab to validate and develop solutions to pressing clinical needs. We have developed/led new drug delivery technologies with a multidisciplinary team that have shown strong potential in ongoing human IBD clinical trials. My lab has utilized both supervised and unsupervised approaches to analyze social media discourse and unstructured data sets for identifying patient needs that are rarely addressed in clinical settings. We have gained insights into patient perceptions around preventative health interventions, such as health screening and diet, including the dearth of evidence-based dietary recommendations to treat IBD (despite strong patient desire for solutions in this domain).
